Tropomyosin-related kinase (TRK) inhibitors
US-11406644-B2 · Aug 9, 2022 · US
Tropomyosin-related kinase (Trk) inhibitors
US11878024B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11878024-B2 |
| Application number | US-202217883350-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 8, 2022 |
| Priority date | Dec 10, 2013 |
| Publication date | Jan 23, 2024 |
| Grant date | Jan 23, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
First claim
Opening claim text (preview).
The invention claimed is: 1. A pharmaceutical composition, comprising one or more pharmaceutically acceptable excipients and 2. A pharmaceutical composition, comprising one or more pharmaceutically acceptable excipients and or a pharmaceutically acceptable salt thereof. 3. A method of treating osteoarthritis in a patient, comprising administering to the patient in need thereof a pharmaceutical composition according to claim 1 to treat the osteoarthritis. 4. A method of treating osteoarthritis in a patient, comprising administering to the patient in need thereof a pharmaceutical composition according to claim 2 to treat the osteoarthritis. 5. The method of claim 3 , wherein the administering is by injection into the patient. 6. The method of claim 4 , wherein the administering is by injection into the patient.
Assignees
Inventors
Classifications
Phosphorus compounds · CPC title
- A61K31/551Primary
having two nitrogen atoms, e.g. dilazep · CPC title
- A61K31/4184Primary
condensed with carbocyclic rings, e.g. benzimidazoles · CPC title
the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title
containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11878024B2 cover?
- Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthr…
- Who is the assignee on this patent?
- Genzyme Corp
- What technology area does this patent fall under?
- Primary CPC classification A61K31/551. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 10 related publications on this page (citations in our corpus or others sharing the same primary CPC).